Table 2.
Diagnosis and therapeutic approach based on various studies.
| Family History | Personal Medical History |
Symptoms | Clinical Diagnosis |
Imaging US, MRI, CT, PET Chest X-Ray |
Biomarkers | Histopathology | Management | Prognosis | Follow-Up |
|---|---|---|---|---|---|---|---|---|---|
| Family cancers are inversely linked with this type of tumor | NAD | NAD | NAD | NAD | β-HCG | Microscopic changes | Fertility-sparing surgery | Histopathology | Every 3 months/ 3 years |
| Pelvic pain | Tumoral mass | Tumoral mass | AFP | Chromosome mapping | Surgery (unilateral oophorectomy) |
Age | Every 6 months/ 2 years |
||
| Nausea | Bleeding | Calcifications | CEA | Buccal swab |
BEP (chemotherapy) |
Staging | Annually/ 10 years |
||
| Bleeding | Casexia | Vascular changes | LDH | Peritoneal washing cytology and Biopsy |
Bilateral oophorectomy and hormone replacement therapy |
Grading | Duration of long-term follow-up is not established |
||
| Amenorrhea | Metastases | Low-resistance flow (Doppler) |
Total hysterectomy |
Assoc. with other germinal tumors |
|||||
| Hermaphroditism | Hemorrhage | Omentectomy | Genetic anomalies | ||||||
| Necrosis | CA-125 | Lymphadenectomy | Biomarker levels | ||||||
| Ascitis (rare) |
Radiotherapy | Residual tumors | |||||||
| Pleuresia (rare) |
Treatment outside reference centers |
NAD—nothing abnormal discovered; β-HCG—beta-human chorionic gonadotropin; AFP—alpha-fetoprotein; CEA—carcinoembryonic antigen; LDH—lactate dehydrogenase; CA-125—cancer antigen 125; BEP—bleomycin sulfate, etoposide phosphate and cisplatin.